CD19 and B-cell acute lymphoblastic leukemia: For blinatumomab, a bispecific T cell engager such as tebentafusp—which targets CD19 instead of gp100 and is approved for the treatment of B cell acute lymphoblastic leukemia—a higher percentage of T cells at baseline was associated with an improved outcome [21].